Although remarkable strides have been achieved in the management of metastatic cutaneous melanoma (CM) with T cell based immunotherapies, limited progress has been made with metastatic uveal melanoma (UM), a rare and aggressive variant that is hypothesized to be immunotherapy-resistant. In this study, we sought to formally define the relative immunogenicity of these two melanoma variants and determine whether endogenous anti-tumor immune responses exist against UM. Here, we report the novel identification of TIL from a subset of UM metastases with robust anti-tumor reactivity, comparable in magnitude to that of CM TIL. The discovery of this immunogenic group of UM metastases has important clinical implications for the role of immunotherapies in the treatment of patients who harbor these unique tumors.
INTRODUCTION
Uveal melanoma (UM) is a rare and aggressive variant of melanoma that has specific origin within the vascular layers of the eye including the choroid, ciliary body, and iris (collectively known as the uvea) (1) . Although UM is the most common intraocular tumor in adults, it accounts for only 3% of all melanomas (2) . With an annual incidence of 5.1 per million in the U.S, UM is significantly less common than cutaneous melanomas (CM). Interestingly, UM and CM have a shared lineage, with each arising from neural crest derived melanocytes that are resident to their respective tissues of origin (3) . Both forms of melanoma, consequently, share prominent expression of prototypic melanocytic differentiation antigens (MDAs) such as MART-1, gp100, and tyrosinase (4) (5) (6) . Despite these similarities, UM can be distinguished from CM by characteristic cytogenetic changes (7) and an unusual predilection to primarily metastasize to the liver (1) . Further, there exists a striking dichotomy between the clinical management of patients with advanced UM and CM. Immunotherapies have become the main treatment modality for metastatic CM based upon substantial evidence that tumor antigens expressed by CM can be vigorously recognized by T cell populations endogenous to the host immune system (8) . By clinically augmenting these immune responses with either systemic cytokines (9) , antibodies targeting T cell checkpoint molecules (10, 11) , or adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) (12) , significant and potentially curative cancer regression can now be achieved in advanced CM patients. However, the role of these immune based therapies for the treatment of metastatic UM remains unclear. Patients with UM are frequently excluded from metastatic melanoma immunotherapy clinical trials because UM is generally thought to be an immunotherapy resistant subtype of melanoma. It has been speculated that since the primary tumor arises in the eye, an immune privileged site, the tumor and its Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR- metastases harbor local immunosuppressive or cellular immuno-evasive factors that render immunotherapies unsuccessful (13) (14) (15) (16) . Another theory proposes that since UM tumors have far fewer somatic mutations compared to sun-exposed CM tumors (17) , there are consequentially fewer potential mutated neo-epitope targets for effective anti-tumor immunity. The poor immunogenicity of UM has been further suggested based upon the comparatively low response rates seen in UM patients enrolled into small pilot trials of immune modulating agents such as interleukin-2 (18) and anti-CTLA-4 antibody (19) (20) (21) . Collectively, these observations have fostered the prevalent belief that UM, in distinction to CM, is a non-immunogenic form of melanoma. However, this hypothesis has largely been based upon inference without formal comparative studies performed directly upon UM and CM metastases to accurately assess their relative immunogenicity. In this study, we aimed to address this deficiency by comparing tumor antigen expression, tumor mutational load, and endogenous anti-tumor immunologic reactivity found in fresh surgically resected UM versus CM metastases. By determining whether tumor specific immune responses naturally exist against UM metastases, we sought to provide insight into the management of this rare melanoma variant with immunotherapies that can exploit these endogenous T cell populations. 
Tumor procurement
Patients typically underwent resection of a single metastatic liver deposit or a closely approximated cluster of tumors using standardized hepatobiliary surgical techniques.
Immediately upon resection, the fresh tumor underwent pathologic assessment, dissection, and processing in the Surgery Branch Cell Production facility in conjunction with a clinical surgical pathologist and research staff. Tumor tissue was assigned a unique liver metastasis identification number (ID #) and allocated for gross and histopathologic analysis, mutational analysis, and TIL culture establishment using methods as described below. Although the main study exclusively focused upon liver metastases, a set of extrahepatic metastases from 8 additional UM patients were incorporated into the tumor driver mutational analysis, as described below.
In situ MRI assessment of tumor melanin content
All patients underwent pre-operative MRI liver imaging as part of their radiographic tumor staging. Quantitative T1-weighted signal intensity measurements (without gadolinium enhancement) of the in situ liver metastases and adjacent normal tissue were obtained using clinical radiology imaging software (Carestream Vue Solutions, version 11.3). Mean tumor and normal intensity were calculated by averaging three separate signal intensity measurements.
Hyperintense tumors were defined as having a mean tumor/normal (T/N) intensity ratio > 1.5.
Hypointense tumors had a mean T/N ratio < 0.7. Mixed intensity tumors had both hyperintense and hypointense components. The T/N signal intensity ratio for each liver metastasis was objectively calculated for each metastasis and scored as either hyperintense (2+), mixed intensity (1+), or hypointense (0), as illustrated in Supplementary Figure 1 .
Gross pathologic assessment of tumor melanin pigmentation
After surgical resection, all liver metastases underwent independent gross pathological assessment and photo documentation by a board certified pathologist who was blinded to the comparative analysis. Each metastasis underwent serial sectioning to assess their melanin pigmentation. Tumors were scored based on their level of pigmentation as either hyperpigmented (2+), mixed pigmented (1+), or hypopigmented (0). 
Immunohistochemical staining analysis of tumor metastases
Surgically resected tumor specimens were fixed in 10% neutral buffered formalin for up to 24 hours and routinely processed. Paraffin-embedded tissue sections of 5 mm were deparaffinized through xylene and graded series of alcohols. Immunohistochemical staining was performed following heat-induced epitope retrieval with target retrieval solution (low pH; DAKO, Carpinteria, CA). Slides were incubated in Tris with 3% goat serum for 15 minutes and then incubated at room temperature with primary antibody for 1 to 2 hours. Immunohistochemical stainining was carried out using the Dako Autostainer or Ventana BenchMark XT Slide Stainer 
Generation and assessment of TIL cultures
Geographically discrete 1 to 2 mm 3 tumor fragments (n=24) were freshly dissected from each tumor metastasis and placed individually in wells of a 24-well culture plate containing complete media with human AB serum and recombinant IL-2 (3000IU/ml) as previously described (22) . FastQC (23) and NGSQCtoolkit (24) . Reads were trimmed and filtered for adapters using Trimmomatic (25) . Alignment was carried out to the human Hg19 reference sequence using BWA-0.7.4 (26) . Alignment files were indexed, sorted and duplicates were removed. Realignment around InDels and base-quality score recalibration was carried out as per the GATK best practices for exome-seq analysis(27). MuTect was used in the high-confidence (HC) mode for calling somatic point mutations(28). The subset of calls that passed the high-confidence filters after the statistical analysis within Mutect were annotated using Annovar (29) 
Statistical Analysis
Fisher's exact test was used to determine associations between dichotomous demographic parameters and the Wilcoxon rank sum test was utilized for the comparison of continuous parameters such as patient age. Non-parametric comparisons between the UM and CM cohorts Further, since UM predominantly metastasizes to the liver, this homogeneous source of metastases would prevent potential site-specific bias in our comparative assessment of tumors.
Patients undergoing liver metastasectomy were stratified into two cohorts, CM and UM, based upon the anatomic origin of their primary melanomas. The CM cohort included 35 patients; 33 of whom had documented primary tumors arising from the cutaneous epithelium and 2 additional patients had primary tumors of unknown origin. Patients with melanoma of unknown origin were included in the CM cohort based upon recent molecular genetic studies which revealed these tumors strongly resembled cutaneous melanomas (32) . The UM cohort included 14 patients who had ophthalmologic documentation that their primary melanoma arose specifically from the uveal tract. The characteristics for each of the patients who underwent liver metastasectomy are shown in Table 1 and the comparison of the CM and UM cohorts are shown in Table 2 . The age (mean and range) and gender distribution of the patients in the two cohorts were similar. At the time of referral to our center, there was a greater trend for the UM patients to have not received prior systemic therapy for their metastatic disease when compared to the CM patients (UM: 71% vs. CM: 37%, P= 0.06). This finding likely reflected the growing availability of approved systemic agents and clinical trial opportunities for patients with metastatic CM during the study 
and CM metastases underwent pathologic examination after resection, we similarly found a significant difference in their gross pigmentation (P = 0.008) ( Figure 1C ). CM metastases were more often visually hypopigmented (0) (CM: 70% vs. UM: 25%) and UM metastases were more often hyperpigmentated (2+) (UM: 44% vs. CM: 20%). Thus, we concluded that despite having common lineage from melanin-producing cells, CM and UM metastases displayed significant differences in their overall melanin content.
Comparison of melanocyte differentiation antigens and MHC expression between CM and UM liver metastases
To better understand the differences observed in melanin pigmentation between the CM and UM liver metastases, we next performed immunohistochemistry (IHC) to compare the cellular expression of proteins associated with melanocyte differentiation. The tumor expression (% of viable cells and staining intensity) for MART-1, gp100, and tyrosinase were prospectively assessed by pathologists blinded to the comparative analysis (Figure 2A 
Comparison of tumor infiltrating lymphocytes found in CM and UM liver metastases
High levels of tumor infiltrating lymphocytes (TIL) have been reported to correlate with favorable prognoses in a variety of solid organ malignancies (34) (35) (36) studies of TIL expanded from CM metastases have found that these infiltrating cells can often recognize antigens expressed by the tumor (37) . Further, the autologous adoptive transfer of such TIL has shown durable and complete tumor regression in metastatic CM (12) . These findings have provided compelling evidence for the natural immunogenicity of CM metastases. However, it is unclear whether UM tumors can similarly elicit adaptive immune responses in vivo. To provide insight, we sought to compare the attributes of TIL found in UM and CM liver metastases. First, the degree of infiltrating T cells (CD3, CD4, and CD8 staining) and B cells (CD20 staining) associated with each of the metastases was prospectively assessed by pathologists blinded to the comparative analysis. From both tumor cohorts, we found significant heterogeneity in the numbers of peripheral and infiltrating T cells which ranged from no lymphocytes detected (0) to extensive lymphoid aggregation occupying over 50% of the tumor field (3+). When the CM and UM metastases were compared, we found no significant differences in the levels of peripheral and infiltrating CD3+, CD4+, or CD8+ T cells between the cohorts (Supplementary Figure 2) . Further, B cells (CD20+ cells) were undetectable in the majority of tumors and also not significantly different between the cohorts.
Having observed that the degree of lymphocytic infiltration was similar between the CM and UM liver metastases, we next sought to assess the phenotypic and functional attributes of the TIL after ex vivo expansion. Consecutive metastatic liver tumors were procured from 8 CM and 13 UM patients during a shared time period. To account for intra-tumoral heterogeneity that might influence TIL growth, 24 geographically discrete tumor fragments were freshly dissected from each of the metastases and placed in culture media containing human IL-2 (3000IU/ml).
After approximately 2 weeks of culturing, we found that the percentage of tumor fragments that could successfully generate TIL were equivalent between the CM and UM tumors (95% vs. 94%, respectively). Each of these independently expanded TIL cultures were then assessed by flow cytometry to determine their percentage of CD8+ and CD4+ T cells. We observed a significant difference between the CM and UM liver metastases in the ratio of these T cell subsets ( Figure   3A ). The TIL cultures from 88% of the CM metastases (7 of 8 CM metastases) were composed predominantly of CD8+ T cells. In contrast, only 23% of UM metastases (3 of 13 UM metastases) gave rise to CD8+ enriched TIL. Cumulatively, the mean percentage of CD8+ T cells in the CM derived TIL cultures was significantly greater than in the UM derived TIL (CM: Figure 3C . The TIL cultures from 88% of the CM metastases (7 of 8 CM metastases) demonstrated mean tumor specific IFN-γ production >100 pg/ml. In contrast, 46% of UM metastases (6 of 13 UM metastases) had mean reactivity above this threshold. Cumulatively, CM derived TIL cultures produced higher mean levels of IFN-γ in response to autologous tumor digest when compared to UM derived TIL cultures (CM: 1044 pg/ml vs. UM: 209 pg/ml, P<0.0001) ( Figure 3D) . Interestingly, however, we identified individual TIL cultures from 46% of UM metastases (6 of 13 UM metastases) (L-UM 3b, 5, 7, 8, 12, and14), with IFN-γ production which was comparable in magnitude to the responses identified from CM TIL ( Figure 3C ). Thus, although specific autologous anti-tumor T cell responses were more prevalent among the CM liver metastases, there was a subset of UM tumors that could also elicit strong tumor reactive T cell responses.
Metastasis hypopigmentation identifies an immunogenic subset of uveal melanoma
Having found that a subset of UM metastases could naturally elicit auto-reactive TIL responses, we next sought to determine if there was a clinically relevant means to prospectively identify UM patients who harbored these immunogenic tumors. Since the majority of CM metastases possessed TIL with autologous tumor reactivity, we postulated that similar adaptive T cell responses might preferentially be found in UM metastases with attributes akin to CM tumors. Pre-operative MRI and gross pathologic examination had demonstrated that the majority of CM liver metastases lacked melanin pigmentation ( Figure 1B) . Thus, we investigated whether the in situ melanin content of UM metastases, as determined by pre-operative MRI imaging, might correlate with the subsequent growth of auto-reactive TIL populations. The liver metastases from 13 consecutive UM patients (described in Figure 3C ) underwent stratification based upon their pre-operative in situ radiographic attributes. MRI signal intensity scores identified four metastases as hyperpigmented (2+) (L-UM 1b, 4, 9, and10), five metastases as mixed pigmented (1+) (L-UM 3b, 5, 6, 11, and 13), and four metastases as hypopigmented (0) (L- UM 7, 8, 12, 14) . Next, the IFN-γ responses from each of the TIL cultures derived from these metastases were assessed based upon the MRI characteristics of their parental tumors (Figure 4 ).
We found that hyperpigmented metastases (2+ MRI signal) uniformly gave rise to TIL cultures (n=96) with low anti-tumor IFN-γ production (mean: 35pg/ml) that did not exceed background control levels. In contrast, the mixed pigmented metastases (1+ MRI signal) generated TIL cultures (n=111) with significantly greater IFN-γ production (mean IFN-γ: 194 pg/ml) (Mixed 
Comparison of tumor mutational profile between CM and UM metastases
Although normal differentiation antigens are common targets for endogenous T cells in melanoma patients, recent studies have demonstrated that unique somatic mutations expressed by tumors can also elicit autologous T cell responses (37) (38) (39) . Further, comparative whole exome sequencing (WES) has revealed sun exposed CM tumors to have the highest number of somatic mutations among common malignancies (40) . These observations have fostered the theory that the unique responsiveness of metastatic CM to a variety of immunotherapy approaches is a direct consequence of endogenous immune responses against neo-epitopes encoded by these large numbers of mutations. Thus, we next sought to determine if the identified subset of immunogenic UM metastases also harbored a greater mutational load that might explain their enhanced T cell recognition. Previously, it has been reported that sun-shielded melanomas, including UM, have far fewer non-synonymous mutations when directly compared with sunexposed CM tumors (17) . However, these analyses were based upon a limited number of UM samples which included a mixture of primary and metastatic tumors. Thus, we first sought to better determine the frequency and characteristics of the non-synonymous mutations occurring in CM and UM metastases. To provide adequate sample numbers for this analysis we obtained 
WES data for 278 CM metastases via The Cancer Genome Atlas (TCGA) data portal and compared these against data from 14 UM metastases from our cohort. Of note, since the TCGA database does not denote the anatomic site of the metastases, the CM data represents metastases from a variety of sites. Protein-altering somatic point mutations for each tumor were determined using a common analytical workflow based upon comparison to matched germline DNA. We found CM metastases had a broad range in mutation number (range: 6-31,250) when compared to UM metastases (range: 15-168). Further, as a group, CM metastases had significantly more somatic mutations when compared to UM metastases (median counts; CM: 282 vs. UM: 73, P<0.0001) ( Figure 5A ).
Next, we compared the tumor cohorts for the frequency of prototypic melanoma associated oncogenic driver mutations including, BRAF, GNAQ and GNA11 ( Figure 5B ). We found BRAF mutations in 53% of the CM metastases (n=278). However, BRAF was not mutated in any of the UM tumors (n=22); (BRAF mutation frequency; CM vs. UM metastases, P<0.0001). In contrast, activating mutations in either of the homologous genes, GNAQ or GNA11, were identified in 91% of the UM metastases, but in only 5% of the CM metastases; (GNAQ/GNA11 mutation frequency; CM vs. UM metastases, P<0.0001).
Finally, we investigated in 12 UM patients whether the mutational frequency identified in their metastases correlated with the autologous anti-tumor reactivity of their respectively derived TIL cultures (n~24 cultures/tumor). When the tumor induced IFN-γ production from each of the TIL cultures was assessed against the number of non-synonymous mutations identified in their respective parental tumors, we found no correlation between the parameters ( Figure 5C ).
Research. 
DISCUSSION
The last 30 years has provided substantial evidence that the human immune system can naturally generate potent immunologic responses against tumor antigens expressed by metastatic cutaneous melanoma (8) . Cancer regression can now be achieved in patients with metastatic CM with mechanistically diverse forms of immunotherapy that augment naturally existing tumor specific T cell responses (9) (10) (11) (12) . However, the role of these immune based therapies for the treatment of metastatic uveal melanoma patients remains unclear. Patients with UM are frequently excluded from metastatic melanoma immunotherapy clinical trials because UM is generally thought to be a non-immunogenic form of melanoma (13) (14) (15) (16) . However, there have not been formal comparative studies performed directly upon UM and CM metastases to accurately assess their relative immunogenicity. In this study, we compared the tumor antigen expression, tumor mutational load, and endogenous anti-tumor immunologic reactivity found in fresh surgically resected UM and CM metastases. By defining the tumor specific immune responses that are naturally found in these metastases, we sought to provide insight into the role for immune based therapies for the management of UM patients. We previously reported that melanoma metastases demonstrate significant heterogeneity in tumor antigen expression and lymphocytic infiltrate based upon their anatomic location in the body (6) . Thus, to avoid potential site-specific bias in the current study, we focused our comparative analysis selectively upon liver metastases resected from UM and CM patients. Our findings revealed that despite having common melanocytic lineage, UM and CM liver metastases were highly dichotomous in their melanin content, tumor differentiation antigen expression, and somatic mutational profile.
The majority of CM liver metastases lacked gross melanin pigmentation, whereas UM liver metastases were more commonly hyperpigmented in appearance. In support of this observation, immunohistochemical profiling revealed that CM metastases had lower cellular expression of proteins associated with melanocyte differentiation, including MART-1 and gp100. Further, we found significant differences in the overall somatic mutational profile between CM and UM liver metastases. Comparative whole exomic sequencing revealed CM metastases had significantly greater mutational burden compared to UM metastases with the melanoma variants also possessing quite different oncogenic driver mutations of the MAPK pathway. Similar to previous reports (41) (42) (43) , nearly all of the UM metastases had GNAQ and GNA11 mutations, while CM metastases commonly had BRAF mutations. Collectively, these comparative studies demonstrate CM metastases to be far more de-differentiated from their melanocytic origin when compared to UM metastases in terms of their mutational profile, tumor antigen expression, and gross melanin pigmentation.
When endogenous immune responses in these highly divergent forms of melanoma were characterized, we further identified marked differences in the phenotype and anti-tumor reactivity of their respective infiltrating lymphocytes. CM TIL were predominantly composed of CD8+ T cells, while UM TIL were CD4+ dominant. Reactivity against autologous tumor was significantly greater in CM TIL compared to UM TIL. However, we identified TIL from a subset of UM patients which had robust anti-tumor reactivity that was comparable in magnitude to that of CM TIL. The identification of this immunogenic group of UM metastasis has not been previously reported and thus, has fostered our interest in determining the specific antigenic Although not completely validated as a clinical biomarker, the MRI assessment of melanin content in UM metastases was found in this study to accurately identify tumors that can elicit a strong endogenous immune response. We are, thus, interested in determining whether immune based therapies may be more effective in the subset of UM patients who harbor these unique immunogenic tumors. To help address these questions, we are conducting the first inhuman adoptive T cell transfer trial dedicated to patients with metastatic UM (NCT01814046).
In this phase II study, patients with metastatic UM undergo surgical metastasectomy to procure tumor tissue for TIL generation. The expanded lymphocytes are then adoptively transferred back 
